Valuation: Incyte Corporation

Market Cap 2.33TCr 2.05TCr 1.9TCr 1.75TCr 3.29TCr 2,25800Cr 3.34TCr 23TCr 8.88TCr 1,10100Cr 8.75TCr 8.56TCr 3,82000Cr P/E 2026 *
56.3x
P/E 2027 * 15.6x
Enterprise Value 1.88TCr 1.66TCr 1.54TCr 1.42TCr 2.65TCr 1,82400Cr 2.7TCr 18TCr 7.18TCr 89TCr 7.07TCr 6.92TCr 3,08600Cr EV / Sales 2026 *
3.29x
EV / Sales 2027 * 2.84x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.78%
1 week+0.03%
Current month+2.94%
1 month+11.77%
3 months+22.23%
6 months+14.41%
Current year+18.14%
1 week 114.5
Extreme 114.505
118.95
1 month 106.48
Extreme 106.48
119.6
Current year 89.25
Extreme 89.25
119.6
1 year 69.7
Extreme 69.695
119.6
3 years 50.27
Extreme 50.27
119.6
5 years 50.27
Extreme 50.27
119.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Free

EVP & Chief Scientific Officer

46,244 0.0231%
16/07/26 Free

Chairperson

1,04,772 0.0524%
16/07/26 Free

Chief Executive Officer

1,84,376 0.0923%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%+0.03%+65.07%+81.90% 2.33TCr
+0.11%-3.98%+13.89%-11.26% 6.63TCr
+0.37%+1.92%+36.33%+199.56% 5.26TCr
+0.51%+37.90%+37.90%+37.90% 4.33TCr
-1.32%-7.38%-57.63%-57.10% 3.86TCr
+1.46%-3.97%+53.17%-27.51% 2.96TCr
-1.81%-9.71%+64.46%-54.90% 2.26TCr
-1.21%+1.12%+1.98%+170.93% 2.02TCr
-0.94%-1.78%+60.62%+121.92% 1.63TCr
+0.33%+3.28%+79.54%+142.98% 1.63TCr
Average -0.17%-2.28%+35.54%+60.44% 3.29TCr
Weighted average by Cap. -0.05%-2.31%+27.70%+51.04%

Financials

2026 *2027 *
Net sales 573.15Cr 504.08Cr 468.29Cr 430.7Cr 807.7Cr 56TCr 822.18Cr 5.6TCr 2.18TCr 27TCr 2.15TCr 2.11TCr 94TCr 615.63Cr 541.45Cr 503Cr 462.62Cr 867.57Cr 60TCr 883.12Cr 6.01TCr 2.35TCr 29TCr 2.31TCr 2.26TCr 1,00900Cr
Net income 43Cr 38Cr 35Cr 32Cr 61Cr 4.17TCr 62Cr 420.23Cr 163.91Cr 2.03TCr 161.47Cr 157.98Cr 7.05TCr 155.88Cr 137.1Cr 127.36Cr 117.14Cr 219.67Cr 15TCr 223.61Cr 1.52TCr 594.04Cr 7.36TCr 585.2Cr 572.54Cr 26TCr
Net Debt -448Cr -394.01Cr -366.04Cr -336.65Cr -631.33Cr -43TCr -642.65Cr -4.38TCr -1.71TCr -21TCr -1.68TCr -1.65TCr -73TCr -585.79Cr -515.2Cr -478.62Cr -440.2Cr -825.51Cr -57TCr -840.31Cr -5.72TCr -2.23TCr -28TCr -2.2TCr -2.15TCr -96TCr
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
23/26/23 $116.69 +0.78% 9,56,259
22/26/22 $115.79 -1.36% 9,98,480
21/26/21 $117.39 +1.50% 19,06,845
20/26/20 $115.65 -1.36% 12,57,145
17/26/17 $117.25 +0.51% 22,32,513
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
116.69USD
Average target price
114.55USD
Spread / Average Target
-1.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock